Hypoplastic Left Heart Syndrome (HLHS) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Hypoplastic left heart syndrome (HLHS) is a complex combination of cardiac malformations that probably results from multiple developmental errors in the early stages of cardiogenesis and that, if left untreated, invariably prove fatal. A variety of chest radiographic findings is seen in patients with HLHS, including an enlarged cardiac silhouette (notably a prominent right atrium), pulmonary venous hypertension, an atrial septal defect, and valvular stenosis or atresia. In HLHS, pulmonary venous blood enters the left atrium, but atrial systole cannot push blood across the atretic or stenotic mitral valve into the hypoplastic left ventricle. Consequently, left atrial blood is shunted across interatrial communication. The interatrial defect can range from a highly restrictive pinhole-sized foramen ovale to a wide, nonrestrictive atrial septal defect. Most commonly, the foramen ovale restricts left-to-right shunting. This restricted flow, coupled with decreased flow through the mitral valve, causes pulmonary venous outflow obstruction, resulting in the typical presentation of a neonate with severe congestive heart failure.

 

HLHS has a reported prevalence of 0.2 per 1,000 live births and occurs twice as often in boys as in girls. Left untreated, HLHS is invariably lethal and is responsible for 25% of early cardiac deaths in neonates.

 

The competitive landscape of Hypoplastic Left Heart Syndrome (HLHS) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Hypoplastic Left Heart Syndrome (HLHS) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hypoplastic Left Heart Syndrome (HLHS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Hypoplastic Left Heart Syndrome (HLHS) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Lomecel-B        Longeveron Inc. Phase 2

2          JRM-001           Japan Regenerative Medicine Co., Ltd.  Phase 3

3          Curosurf           Chiesi Farmaceutici S.p.A.         Phase 1

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033